title: The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
authors.forename: Christoph
authors.initials: C
authors.lastname: Schmid
authors.forename: Michael
authors.initials: M
authors.lastname: Brändle
mesh_terms: D000077465:Cabergoline; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000188:drug therapy*; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline